IYIlker Kemal Yucel

Ilker Kemal Yucel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilker Kemal Yucel has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of haematologic parameters with persistent rheumatic heart disease stage in children: a pilot study

    by Nida Gülderen Kalay Şentürk, Sevim Aslı Ehlil, Ali Karakaş, Samed Cihad Çelik, Nergis Akay, Büşra Albayrak, Hazal Cansu Çulpan, İlKer Kemal Yücel, Özgür Kasapçopur, Reyhan Dedeoğlu

    Purpose: Rheumatic heart disease remains a major cause of cardiovascular morbidity in children. Although echocardiography is central to diagnosis and staging, it does not directly reflect inflammatory processes that may contribute to ongoing valvular damage. This study aimed to evaluate the association between baseline haematologic parameters and persistent rheumatic heart disease stage in children with prior acute rheumatic fever. Methods: In this single-centre retrospective pilot study, 45 children with persistent rheumatic heart disease were classified as Stage A ( n = 23), Stage B ( n = 14), or Stage C ( n = 8) according to the 2023 World Heart Federation echocardiographic staging framework. Baseline laboratory values obtained during acute presentation were analysed. Clinical and laboratory variables were compared across stages using non-parametric tests. Binary logistic regression identified factors associated with advanced disease (Stage B–C vs Stage A). Results: Markers reflecting acute inflammatory activity, including leukocyte counts and derived indices, did not differ significantly among stages. In contrast, red cell distribution width, mean platelet volume, and platelet distribution width differed significantly. In multivariable analysis, red cell distribution width, and mean platelet volume were independently associated with advanced persistent rheumatic heart disease stage, with higher values linked to increased odds of Stage B–C disease. Conclusion: Red cell distribution width and mean platelet volume were associated with advanced stages of persistent paediatric rheumatic heart disease. These widely available haematologic markers may complement echocardiographic assessment. Larger prospective studies are needed to define their clinical utility. Trial registration: Not applicable (retrospective study).

  • Biodegradable stents and occluders in CHD: current evidence, biomechanical constraints, and translational challenges

    by Sercin Ozkok, Banu Kose, Ilker Kemal Yucel, Tansu Golcez, Muhammad Umair, Mohammed Eid Kaakeh, Mohammed Saloukha, Tuba Banaz, Berk Tutuncuoglu, Muhammed Faruk Kazanbas, et al.

    Congenital heart disease (CHD) often requires device implantation during childhood, when somatic growth and changing haemodynamics place particular demands on permanent implants. Metallic stents and nitinol occluders are effective, but their lifelong persistence can complicate repeat interventions, limit imaging surveillance, and interfere with growth-related remodelling. This review examines the rationale, current evidence, biomechanical constraints, and translational challenges of biodegradable stents and occluders in CHD. These devices aim to provide temporary mechanical support followed by controlled resorption, thereby reducing the burden of permanent foreign material and preserving future interventional options. Translation to congenital practice is, however, not straightforward, as early structural integrity must be balanced against predictable degradation, adequate endothelialisation, and compatibility with somatic growth. Experience from adult coronary bioresorbable scaffolds cannot be directly extrapolated to paediatric anatomies or timelines. Biodegradable septal occluders have accumulated more clinical experience and appear closer to routine use, whereas biodegradable vascular stents remain largely investigational and lack sufficient long-term outcome data to support broader adoption. Further long-term studies in paediatric and congenital populations are needed before biodegradable implants can be recommended as standard alternatives to permanent devices in CHD.


  • Open Access

    Kalp ve Damar Cerrahi - Konjenital Kalp Cerrahisi (Cilt 3)

    by Merjem Purelku, Gamze Tanrıverdi, Ayşe Sarıoğlu, Canan Ayabakan, Osman Yılmaz, Tuğçin Bora Polat, Merve Maze Aydemir, Feyza Ayşenur Paç, Serçin Özkök, Uğur Dikkaş, et al.

  • Open Access

    Atrial and ventricular strain changes after transcatheter pulmonary valve replacement in patients with repaired tetralogy of Fallot: a feature tracking cardiac MRI study

    by Sercin Ozkok, Hatice Ozge Ciftci, Ilker Kemal Yucel, Dursun Muhammed Ozdemir, Kevser Banu Kose, Ahmet Celebi, Kerem Pekkan

    Purpose: In patients with repaired tetralogy of Fallot, transcatheter or surgical pulmonary valve replacement is recommended. However, it is not clear whether pulmonary valve replacement preserves systolic and diastolic functions of both ventricles. The aim of the study is to investigate the impact of transcatheter pulmonary valve replacement on atrial and ventricular myocardial strain changes by feature-tracking cardiac magnetic resonance imaging. Materials and methods: Cardiac magnetic resonance imaging of 18 patients (median age 14.5 years) with repaired tetralogy of Fallot before and after transcatheter pulmonary valve replacement were retrospectively analyzed. Feature tracking strain for both left and right atria and ventricles was performed. Cardiac magnetic resonance imaging parameters (volume and function) and strain characteristics (atria and ventricles) were compared before and after transcatheter pulmonary valve replacement. The Wilcoxon rank-sum and Spearman correlation test was used. Results: After pulmonary valve replacement, right ventricular end-diastolic volume, end-systolic volume, and stroke volume decreased, whereas left and right ventricular ejection fractions remained unchanged. Reservoir, conduit and pump strain measurements improved for both left (P = 0.003, P = 0.001, and P = 0.006) and right atria (P = 0.013, P = 0.004, and P = 0.015). Global left ventricular circumferential, longitudinal, and radial strains improved (P = 0.001, P = 0.043, and P = 0.002, respectively). Right ventricle global circumferential strain significantly improved with no significant change in the longitudinal and radial strains (P = 0.007, P = 0.068, and P = 0.055, respectively). Conclusion: Transcatheter pulmonary valve replacement significantly enhances atrial and ventricular strain parameters, indicating a positive impact on overall myocardial function. Feature-tracking cardiac magnetic resonance imaging may offer a comprehensive, non-invasive evaluation of myocardial strain changes in patients with repaired tetralogy of Fallot after pulmonary valve replacement, which leads to improvement of indications and outcomes.


  • Open Access

    Comparative Safety and Efficacy of Rivaroxaban Versus Warfarin in Pediatric Patients Following the Fontan Procedure: A Retrospective Cohort Study

    by Mustafa Kemal Avşar, Yasin Güzel, İbRahim Özgür Önsel, Barış Kırat, İlKer Kemal Yücel, Cenap Zeybek, Deniz Yorgancılar

    Background: The extracardiac Fontan procedure, a palliative intervention for single‐ventricle physiology, is associated with significant thromboembolism and bleeding risks. Warfarin has been the standard anticoagulant, but its limitations have prompted exploration of nonvitamin K oral anticoagulants, such as rivaroxaban. Objective: To compare the safety and efficacy of rivaroxaban vs. warfarin as postoperative anticoagulation in pediatric patients following the extracardiac Fontan procedure, focusing on thromboembolic events, bleeding complications, and treatment adherence. Methods: This retrospective cohort study included 369 pediatric patients (aged 3–17 years) who underwent the extracardiac Fontan procedure at a single center from 2015 to 2022, selected from 412 cases reviewed, with 43 excluded due to incomplete follow‐up or comorbidities. Patients received either warfarin ( n = 177) or rivaroxaban ( n = 192) for anticoagulation. Baseline characteristics, including age, sex, body weight, and pulmonary artery pressure, were comparable between groups. Anticoagulation was initiated on postoperative Day 1 per institutional protocol, excluding aspirin to standardize thromboembolism prevention due to high risk in nonanticoagulated patients. Warfarin was titrated to an international normalized ratio (INR) of 2.0–3.0, while rivaroxaban was dosed per European Medicines Agency guidelines. Outcomes included thromboembolic events (graft thrombosis, pulmonary embolism, and transient ischemic attacks [TIAs]), major and minor bleeding, mortality, and treatment discontinuation over a mean follow‐up of 5 years. TIAs were defined per American Heart Association guidelines as transient neurological dysfunction lasting less than 24 h without infarction on neuroimaging. Statistical analyses used Fisher’s exact test, Kaplan–Meier survival analysis, and multivariable logistic regression, with p < 0.05 indicating significance; the study was designed to detect a 3% difference in major bleeding. The limited number of thromboembolic events resulted in wide confidence intervals, limiting precision in between‐group comparisons. Results: Thromboembolic events occurred in 5.1% ( n = 9) of warfarin patients and 2.1% ( n = 4) of rivaroxaban patients (OR = 2.5, 95% CI: 0.8–8.2). Major bleeding was significantly higher with warfarin (3.4%, n = 6; 4 intracranial and 2 gastrointestinal) than rivaroxaban (0.5%, n = 1; gastrointestinal; OR = 7.0, 95% CI: 1.2–40.8). Minor bleeding rates were 9.0% (warfarin) vs. 5.7% (rivaroxaban). Two warfarin‐related deaths (intracranial hemorrhage and systemic embolism post‐TIA) were recorded; none occurred with rivaroxaban. Treatment discontinuation was higher with warfarin (5.1% vs. 0.5%). Conclusions: Rivaroxaban demonstrated a superior safety profile compared to warfarin, with significantly lower major bleeding rates, no associated mortality, and improved treatment adherence in pediatric Fontan patients. Its fixed‐dose regimen simplifies management, although implementation requires consideration of cost and formulation access. Risk‐stratified approaches and larger prospective trials are needed to optimize anticoagulation strategies.


  • Open Access

    Myocardial Protection in Complete AVSD Repair: A Decade of Comparative Outcomes Between Custodiol‐HTK and Blood Cardioplegia

    by Mustafa Kemal Avşar, Yasin Güzel, İbRahim Özgür Önsel, Barış Kırat, İlKer Kemal Yücel, Cenap Zeybek, Deniz Yorgancılar

    Objective: This study compared early postoperative outcomes of Custodiol‐HTK versus cold intermittent blood cardioplegia in patients undergoing complete atrioventricular septal defect (CAVSD) repair. Methods: From January 2012 to December 2022, we retrospectively analyzed 305 patients undergoing CAVSD repair at our center. Patients were divided into two groups based on cardioplegia: Group 1 received Custodiol‐HTK ( n = 159), and Group 2 received cold intermittent blood cardioplegia ( n = 146). Outcomes that were compared included mortality, ECMO requirement, cross‐clamp and cardiopulmonary bypass (CPB) times, cardioplegia doses, valvular edema (assessed intraoperatively via a visual scale), postoperative intubation time, ICU stay, and hospital stay. Results: Mortality was 1.9% in Group 1 versus 8.2% in Group 2 ( p = 0.01). ECMO was required in 0.6% of Group 1 versus 11.0% of Group 2 ( p < 0.001). Cross‐clamp time (56 ± 12 min vs. 76 ± 16 min, p < 0.001) and CPB time (83 ± 14 min vs. 97 ± 17 min, p = 0.002) were shorter in Group 1. Cardioplegia doses were 1 in Group 1 versus 4.7 ± 1.2 in Group 2 ( p < 0.001). Intubation time, ICU stay, and hospital stay were significantly shorter in Group 1 ( p < 0.01 for each). Conclusion: Custodiol‐HTK was associated with improved early outcomes, including reduced mortality, ECMO use, and shorter operative and recovery times, in CAVSD repair. It appears to offer superior myocardial protection, particularly in complex cases, though potential risks such as hyponatremia require careful perioperative management.


  • Open Access

    Fetal hypoplastic left heart syndrome: key factors shaping prognosis

    by Büşra Cambaztepe, Oya Demirci, Işıl Ayhan, Abdullah Alpınar, İlKer K. Yücel

    Objectives: The purpose of the study is to estimate factors affecting survival in prenatally diagnosed hypoplastic left heart syndrome (HLHS) and echocardiographic features predicting poor prognosis and early neonatal death. Methods: This study was designed as a retrospective cohort study. Cases of hypoplastic left heart syndrome diagnosed in the prenatal period between 2014 and 2023 were extracted from electronic medical records. Demographic data, echocardiographic features, results of genetic testing, pregnancy outcomes, and postnatal outcomes were analyzed. Results: Eighty-three prenatally diagnosed fetal HLHS cases were analyzed. Overall, survival during the study period was 26.5 %, and survival among live births was 35.4 %. Survival analysis has shown that the majority of deaths occurred during the neonatal period. Out of 62 live births, 47 had Norwood procedures, six had balloon procedures and three had hybrid procedures. Eleven out of 47 who had the Norwood procedures went on to have a Glenn operation, and only three had full Fontan palliation. The presence of additional extra-cardiac anomaly, need for extracorporeal membrane oxygenation (ECMO), bidirectional flow at pulmonary veins on color Doppler, and low birth weight are associated with survival and early neonatal death. Tricuspid regurgitation, restrictive foramen ovale, and fetal growth restriction (FGR) are not associated with survival. HLHS evolved from critical aortic stenosis has better survival rates. Conclusions: Extra-cardiac anomaly, need for ECMO, bidirectional flow at pulmonary veins, and low birth weight were negatively associated with survival and early neonatal death. The survival rate was higher among HLHS cases that had evolved from critical aortic stenosis.


  • Percutaneous Device Closure of Perimembranous Ventricular Septal Defects Associated with Aortic Valve Prolapse and Aortic Regurgitation

    by Ilker Kemal Yucel, Ibrahim Halil Demir, Murat Kardas, M. Orhan Bulut, Murat Surucu, E. Hekim Yilmaz, R. Irem Yekeler, Ahmet Celebi

    The progression of aortic regurgitation (AR) in perimembranous ventricular septal defects (pVSD) remains uncertain; research indicates that the accompanying AR tends to worsen over time. There is controversy surrounding the percutaneous closure of defects in patients with pVSD associated with aortic valve prolapse (AVP) and AR. Our research focused on transcatheter closure for pVSD accompanied by AVP, AR, and septal aneurysm, with the aim of addressing challenges through device placement in aneurysmal tissue to eliminate the Venturi effect. We studied 44 patients with AVP, AR, and septal aneurysm who underwent transcatheter device closure. The mean age and weight were 10.5 ± 4.0 years and 36.0 ± 15.1 kg, respectively. Transcatheter closure was attempted in 44 patients. One case (2.3%) was referred to surgery, while the procedure was successfully completed in 43 out of 44 patients (97.7%). Early complications were minimal. Embolization of the device to the pulmonary artery was observed in one patient; upon re-evaluation, significant aneurysm tissue damage was detected, leading to a referral for surgery. Additionally, three patients (6.9%) developed permanent incomplete right bundle branch block (iRBBB). The median follow-up time was 43 months. During the follow-up period, AR progressed in only 1(2.3%) patient, while AR in 7(16.3%) patients regressed markedly. Follow-up assessments demonstrated high rates of complete occlusion; the rates at immediate, 24 h, 6 months, and 1 year were assessed as 72, 83.7, 93, and 95.3%, respectively. Transcatheter device closure of pVSD offers a minimally invasive, safe, effective, and alternative treatment option for patients with pVSD associated with AVP and AR.


  • Open Access

    Transcatheter pulmonary artery debanding: Is it effective in every patient?

    by İbRahim Halil Demir, Dursun Muhammed Özdemir, Selma Oktay Ergin, İlKer Kemal Yücel, Murat Sürücü, Murat Çiçek, Numan Ali Aydemir, Ahmet Çelebi

    Background: This study aimed to present our experience with transcatheter pulmonary debanding, focusing on patient outcomes. Methods: The retrospective study was conducted with 32 patients (17 males, 15 females; mean age: 3.6±2 years; range, 0.5 to 8.8 years) who underwent transcatheter pulmonary debanding between January 2010 and January 2024. The patients were evaluated in two groups. In Group 1 (n=24), total debanding was targeted for patients with spontaneously closed or restrictive ventricular septal defects or those suitable for transcatheter ventricular septal defect closure. In Group 2 (n=8), palliative debanding was utilized in children with ongoing band requirement. Results: The median body weight was 15 kg. In Group 1, the mean right ventricle-to-aortic pressure ratio (RVp/Aop) was 0.91±0.21 before the procedure, which decreased to a mean of 0.33±0.20 after the procedure. In Group 2, the mean RVp/Aop was 1.31±0.47, which decreased to 0.77±0.13 after transcatheter palliative debanding. The mean peripheral oxygen saturation was 80±6% before the procedure and 94±2.5% after the procedure. Transcatheter debanding was successful in all patients when surgical pulmonary banding was performed with 6-0 Prolene and polytetrafluoroethylene band material. Conclusion: Transcatheter banding is a safe and effective procedure that minimizes the need for reoperation.